Vaxcyte Corporate Presentation

VAX-PG: Periodontitis Vaccine Program Therapeutic Vaccine Targeting Gingipains to Address Large, Underserved Market о Unmet Need VAX-PG: Multivalent Therapeutic Vaccine Program Status Periodontal disease is a chronic oral inflammatory disease leading to destruction of soft & hard tissues supporting the teeth Highly prevalent: 65 million US adults afflicted • Significant morbidity and lost productivity: >$50B in lost productivity in 2010 Associated with increased risk of heart attack, stroke, cardiovascular disease, and Alzheimer's Disease • Incorporates proprietary combination of known virulence factors of keystone pathogen • Preclinical model demonstrated protein-specific IgG response following immunization and protected mice from P. gingivalis- elicited oral bone loss Initial goal to develop therapeutic vaccine that slows or stops disease progression Preclinical proof of concept published in Journal of Clinical Periodontology Next milestone: Nominate final vaccine candidate in 1H 2022(1) MOA & Key Data Restoration of balanced microbiota by interrupting underlying inflammatory condition A. viscosus Pgingivalis * 伞 Sall HA1 P. gingivalis MFA1 Gingival epithelial cells Sgordan ABC to CEJ Length (mm) 0.251 0.20- 0.15- 0.10. - control No Vaccine + control VAX-PG/Alum VAX-PG/MPL VAX-PG Challenge Study Results Immunization with all formulations of VAX-PG provided significant protection against oral bone loss compared to the unvaccinated control (p<0.01) (1) Guidance provided as of November 10, 2021. 31 Huang et.al. J Clin Periodontol. 2019 Feb;46(2):197-205

View entire presentation